Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 18, 2018. The document serves as a transaction notification regarding a specific securities transaction involving a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports solely on a specific share acquisition transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of Ordinary Shares via dividend re-investment under the Company's Performance Share Plan.
- Transaction Date: October 12, 2018.
- Price: £14.516 per share.
- Volume: 2,083.089 shares.
- Location: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It documents a routine compliance disclosure for a PDMR transaction.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction is subject to a 2-year holding period as part of the Performance Share Plan.
Key Facts for Investor Verification
- The transaction involves Mr. S Dingemans, Chief Financial Officer.
- The acquisition was funded by the re-investment of dividends paid on October 11, 2018.
- The shares acquired are subject to a 2-year holding period.
- This filing does not contain quarterly or annual financial performance data.